Literature DB >> 26984004

The influence of alcohol oral intake on the effects of 35% CO2 challenge. A study in healthy volunteers.

Fiammetta Cosci1, Koen Schruers2, Carlo Faravelli1, Eric Griez2.   

Abstract

OBJECTIVE: Alcohol use disorders and panic disorder co-occur at a rate that exceeds chance significantly. The underlying mechanism of alcoholism associated with anxiety has rarely been examined using experimental methodologies. The present study in healthy volunteers tested whether alcohol consumption reduces anxiety associated with a panic-challenge procedure (35% CO2 challenge).
METHODS: The study design was placebo-controlled, double-blind, randomized. Eight healthy volunteers were enrolled; all subjects had an alcohol and a placebo oral intake according to a crossover design. After each consumption the subjects underwent the 35% CO2 challenge and a series of anxiety symptom assessments.
RESULTS: After the alcohol intake, the subjects presented a significant reduction in the anxiety state associated with the challenge procedure. The Panic Symptom List score is significantly lower after alcohol intake (P = 0.032), as compared with the placebo, and the Visual Analogue Anxiety Scale shows a trend to be lower after alcohol intake (P = 0.111).
CONCLUSIONS: Moderate doses of alcohol acutely decrease the response to a 35% CO2 challenge in healthy volunteers. These results lend support to the pharmacological anxiolytic effect of alcohol and suggest that this property may reinforce the drinking behaviour among those with high levels of anxiety.

Entities:  

Year:  2004        PMID: 26984004     DOI: 10.1111/j.0924-2708.2004.0077.x

Source DB:  PubMed          Journal:  Acta Neuropsychiatr        ISSN: 0924-2708            Impact factor:   3.403


  1 in total

1.  State anxiety and alcohol choice: Evidence from experimental and online observational studies.

Authors:  Maddy L Dyer; Alexander G Board; Lee Hogarth; Steph F Suddell; Jon E Heron; Matthew Hickman; Marcus R Munafò; Angela S Attwood
Journal:  J Psychopharmacol       Date:  2020-08-27       Impact factor: 4.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.